{
    "clinical_study": {
        "@rank": "126045", 
        "arm_group": [
            {
                "arm_group_label": "Single ascending dose in Caucasian men", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Age-effect in Caucasian men", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Gender-effect in Caucasian women", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Single ascending dose in Japanese men", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo: Single ascending dose in Caucasian men", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Placebo: Age-effect in Caucasian men", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Placeo: Gender-effect in Caucasian women", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Placebo: Single ascending dose in Japanese men", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and tolerability of single doses of\n      TA-8995 in healthy Caucasian and Japanese volunteers."
        }, 
        "brief_title": "Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects", 
        "completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Caucasian men aged 18-55 years and \u226565 years\n\n          -  Women of non-childbearing potential\n\n          -  Japanese men aged 18-55 years\n\n          -  Subjects were deemed healthy on the basis of medical history, physical examination,\n             Electrocardiogram (ECG), vital signs and safety tests of blood and urine\n\n          -  Subjects were able to give fully informed written consent\n\n        Exclusion Criteria:\n\n          -  HDL-C level \u22652.59 mmol/L\n\n          -  Abnormal Holter ECG\n\n          -  Family history of long QT syndrome, hypokalaemia or Torsade de Pointes\n\n          -  Vital signs or 12-lead ECG values outside the acceptable range\n\n          -  Positive tests for hepatitis B and C, HIV 1 and 2\n\n          -  Positive urine pregnancy test (women only)\n\n          -  Severe adverse reaction or allergy to any drug\n\n          -  Drug or alcohol abuse\n\n          -  Smoking within the 6 months before dosing with TA-8995 (Caucasian subjects), or\n             smoking more than 10 cigarettes daily (Japanese subjects)\n\n          -  Over-the-counter or prescribed medication up to 7 days or 5 half-lives (whichever was\n             longer) before dosing with TA-8995\n\n          -  Consuming food or drinks containing grapefruit or cranberry within the 7 days before\n             dosing\n\n          -  Participation in other clinical trials, or loss of more than 450 mL blood within the\n             previous 3 months\n\n          -  Clinically relevant abnormal findings at the screening assessment\n\n          -  Clinically relevant abnormal medical history or concurrent medical condition\n\n          -  Possibility that volunteer would not cooperate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878474", 
            "org_study_id": "TA-8995-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single ascending dose in Caucasian men", 
                "description": "TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Age-effect in Caucasian men", 
                "description": "Drug: TA-8995 25 mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gender-effect in Caucasian women", 
                "description": "Drug: TA-8995 25 mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single ascending dose in Japanese men", 
                "description": "Drug: TA-8995 25, 50, 100 and 150 mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo: Single ascending dose in Caucasian men", 
                "description": "Single ascending dose in Caucasian men", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo: Age-effect in Caucasian men", 
                "description": "Age-effect in Caucasian men", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placeo: Gender-effect in Caucasian women", 
                "description": "Gender-effect in Caucasian women", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo: Single ascending dose in Japanese men", 
                "description": "Single ascending dose in Japanese men", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "MT-8995", 
            "Dyslipidemia", 
            "Cholesteryl ester transfer proteins"
        ], 
        "lastchanged_date": "June 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "Hammersmith Medicines Research (HMR)"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, First Time-in-humans Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Escalating Doses of TA-8995 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Hammersmith Medicines Research (HMR)", 
            "last_name": "Steve Warrington, MA MD FRCP FFPM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "336 hours post dose"
            }, 
            {
                "measure": "Laboratory tests (haematology, biochemistry and urinalysis)", 
                "safety_issue": "Yes", 
                "time_frame": "336 hours post dose"
            }, 
            {
                "measure": "Vital signs (supine systolic and diastolic blood pressure, heart rate and body temperature)", 
                "safety_issue": "Yes", 
                "time_frame": "336 hours post dose"
            }, 
            {
                "measure": "Peak concentration (ng/mL) of TA-8995", 
                "safety_issue": "No", 
                "time_frame": "336 hours post dose"
            }, 
            {
                "measure": "Time of peak concentration (hr) of TA-8995", 
                "safety_issue": "No", 
                "time_frame": "336 hours post dose"
            }, 
            {
                "measure": "Area under the concentration-time curve (mg/L\u30fbhr) up to 24 h (AUC0-24), 72 h (AUC0-72), 168 h (AUC0-168), 336 h (AUC0-336) and infinity (AUC0-\u221e) of TA-8995", 
                "safety_issue": "No", 
                "time_frame": "336 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878474"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Plasma Cholesterol Ester Transfer Protein (CETP) activity (%) and concentration (mg/mL)", 
            "safety_issue": "No", 
            "time_frame": "336 hours post dose"
        }, 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}